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it disproportionately affects patients with 
T-cell-mediated orphan diseases like refrac-
tory HLE.  Copyright © 2010 S. Karger AG, Basel 
 Case Report 
 A 43-year-old male painter consulted 
us for long-standing, disfiguring and pain-
ful plaques on his sun-exposed lower arms 
and face. The development of the lesions 
had begun 18 years prior to presentation. 
Intensely inflamed and hyperkeratotic 
plaques were observed on both extensor 
sides of the lower arms, sparing the wrist-
watch area, on the ridge of the nose, and on 
both helices and cheeks ( fig. 1 a). A biopsy 
revealed hyperkeratotic, pseudoepithelio-
matous hyperplasia of the epidermis with 
interface and deep lymphocytic infiltra-
tion, and PAS+ thickening of the basal 
membrane ( fig. 1 c). Antinuclear, anti-
DNA and SS-A and SS-B antibodies were 
in the normal range. On the basis of the 
clinical presentation and histology, the
diagnosis of chronic cutaneous HLE was 
made. The patient did not fulfill the Amer-
ican College of Rheumatology criteria for 
systemic lupus erythematosus (SLE). Pre-
viously, therapeutic trials with high-po-
tency topical corticosteroids in combina-
tion with keratolytic agents, cryothera - 
py, oral prednisone, hydroxychloroquine, 
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 Abstract 
 Background/Aims: Hypertrophic lupus er-
ythematosus (HLE) produces not only dis-
figuring and long-lasting skin changes, but 
also proves to be particularly resistant to 
therapy. In a patient with a disease refrac-
tory to conventional therapy, we observed 
a predominantly CD4+ T cell infiltrate that 
we sought to target therapeutically.  Meth-
ods: The patient was treated with the 
CD11a-directed monoclonal antibody efa-
lizumab together with 10 mg isotretinoin 
and 5 mg prednisone.  Results: Within 6 
months, the inflammatory hyperkeratotic 
plaques were almost completely healed, 
with minimal residual erythema and scar-
ring. The cutaneous lupus activity and se-
verity index score decreased from 8 to 4 of 
a total of 14 points, and pseudoepithelio-
matous hyperplasia and CD4 T cell infil-
trates within the lesions were reduced.  Con-
clusion: HLE features interface dermatitis 
and epidermal hyperplasia, which are both 
explainable by T-cell-mediated immuno-
logic effects. Correspondingly, our case re-
sponded well to the treatment with efali-
zumab. While the withdrawal of efalizumab 
from the market leaves patients with psoria-
sis many other options for effective therapy, 
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dapsone, azathioprine and cyclosporine 
had been ineffective. Partial disease con-
trol was achieved only by a combination of 
systemic prednisone with azathioprine 
and isotretinoin. Azathioprine was subse-
quently substituted by mycophenolate 
mofetil. After 4 years, however, the effica-
cy was lost and the plaques recurred.
 Since cutaneous lupus erythematosus 
is mainly T cell mediated  [1, 2] and we had 
identified substantial CD4+ lymphocytic 
infiltrates in our patient’s lesions ( fig. 1 c), 
we chose at this point to treat the patient 
with the T-cell-blocking agent efalizumab, 
which was available at the time for the 
treatment of plaque-type psoriasis. Efali-
zumab is a recombinant humanized IgG1 
monoclonal antibody that specifically tar-
gets T cells, leading to the subsequent in-
hibition of T cell activation. The efalizu-
mab treatment (initial dose of 0.8 mg/kg 
body weight followed by 1 mg/kg body 
weight weekly) was initiated in February 
2008, and mycophenolate mofetil was 
stopped after 2 months of overlap with 
efalizumab, while the treatment with 5 mg 
prednisone and 10 mg isotretinoin was 
continued. Within 6 months, the inflam-
matory hyperkeratotic plaques were al-
most completely healed, with minimal re-
sidual erythema and scarring ( fig. 1 a, b). A 
biopsy during the efalizumab treatment 
showed a significant reduction in pseudo-
epitheliomatous hyperplasia and CD4+
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 Fig. 1. Lower arms of the patient in November 2007 ( a ) and after 6 months of efalizumab in August 2008 ( b ). 
CD4 (red cells) and hematoxylin-eosin stain of a plaque before treatment ( c ) and after 10 months of efalizumab 
( d ).  e CLASS during treatment with efalizumab. Arrow: stop of efalizumab treatment. 
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T cell infiltrates ( fig. 1 d). The clinical dis-
ease activity, as assessed by the cutaneous 
lupus activity and severity score (CLASS) 
 [3] , decreased from 8 to 4 ( fig. 1 e), reflect-
ing persisting scars and low-grade erythe-
ma. However, reported cases (3 confirmed, 
and 1 unconfirmed but suspected case)
of the demyelinating disease progressive 
multifocal leukoencephalopathy  [4] have 
resulted in efalizumab withdrawal from 
sales in Switzerland in the spring of 2009, 
and the treatment of our patient was sus-
pended, resulting in a flare of disease ac-
tivity within 2 weeks ( fig. 1 e). We did not 
observe any side effects such as arthralgia 
or new autoantibodies during or after the 
therapy with efalizumab.
 Concept of HLE: Epidermal 
Hyperplasia and Interface Dermatitis 
 HLE or verrucous lupus erythematosus 
was first described in 1942 by Bechet  [5] as 
a very rare form of cutaneous lupus, usu-
ally as a manifestation of discoid, but
in rare cases also of subacute cutaneous
or SLE. It manifests itself in sharply
demarcated, livid-to-intensely-erythema-
tous papules or broadly based plaques with 
keratotic surfaces, with residual atrophic 
scars upon regression. The extensor side of 
the forearms, the face and the upper back 
can be involved. In the literature, the de-
scription varies somewhat from squa-
mous, violet and painful papules and 
blackish hyperkeratotic ulcers  [6] to depig-
mented atrophic plaques on the back, hy-
perkeratotic nodular papules on the upper 
extremities  [7] and disseminated kerato-
acanthoma-like papulonodular verrucous 
lesions  [8] . In histology, follicular hyper-
keratosis with hydropic changes within 
the basal membrane and periadnexal lym-
phocytic infiltrates are found. Almost al-
ways, epidermal hyperplasia and vacuolar 
degeneration of the basal membrane are 
found. In direct immunofluorescence, 
most patients show IgG and IgM on the 
dermoepidermal border  [8, 9] . The closest 
differential diagnoses are spinocellular 
carcinoma and verrucous lichen planus. 
Both diagnoses can be concomitant with 
HLE  [7, 10, 11] , and spinocellular carcino-
ma in particular has been described to de-
velop within verrucous HLE plaques after 
sun exposure. In addition, keratoacantho-
ma, hypertrophic actinic keratosis, nodu-
lar prurigo and psoriasis vulgaris must be 
ruled out  [6, 8] .
 HLE has the feature of epidermal hy-
perplasia in common with psoriasis. Re-
cently, interleukin-21  [12] and interleukin-
22  [13] have been shown to be responsible 
for this phenomenon in psoriasis by acti-
vating the proliferation of keratinocytes 
via sustained extracellular signal-regulat-
ed kinases 1 and 2, which are both overex-
pressed in psoriatic skin. Besides inducing 
epidermal proliferation, the CD4+ T-help-
er-cell-produced interleukin-21 controls 
the differentiation and functional activity 
of T cells, B cells and NK cells, and renders 
effector T cells resistant to T regulatory 
immunosuppression  [14] . It also stimu-
lates epithelial cells and fibroblasts to pro-
duce inflammatory mediators. Interest-
ingly, interleukin-21 has been found to be 
overexpressed in lupus erythematosus  [15] 
and positively implicated in the pathogen-
esis in a murine lupus model  [16] , and even 
an interleukin-21 receptor polymorphism 
has been identified as an independent risk 
factor for lupus erythematosus  [17] . Inter-
leukin-21 could be partly responsible as 
well for the readily observable, long-last-
ing immune infiltrates in HLE, as overex-
pression of this cytokine has resulted in 
the massive accumulation of CD8+ mem-
ory T cells  [18] . Interleukin-22, on the oth-
er hand, does not seem to play an impor-
tant role in lupus, as its serum levels have 
even been found to be lowered  [19] . There-
fore, considering the still very limited data 
available on lupus erythematosus and epi-
dermal hyperplasia, treatment with mono-
clonal antibodies against interleukin-21 
could be a valuable option for HLE by ad-
dressing both the T cell infiltrate and epi-
dermal hyperplasia.
 A pathognomonic histological feature 
of cutaneous lupus erythematosus is the 
involvement of the dermoepidermal junc-
tion zone. Lymphocytes line up and can 
obscure this region in a ‘lichenoid’ histo-
logical pattern  [20] . Damage to this area 
leads to later scarring caused by the dis-
ease, very much unlike psoriasis where in-
volved skin is typically able to heal without 
leaving a trace, even after severe momen-
tary pathology. In all types of lupus, in-
flammation shows phototropism, which 
has recently been identified to correlate 
with intercellular adhesion molecule 1 ex-
pression due to UVA and UVB rays  [21] , 
attracting lymphocytes in the upper der-
mis. The infiltrate in cutaneous lupus ery-
thematosus has been shown to consist 
mostly of T cells with a predominance of 
CD4+ over CD8+ T cells  [1, 2] . When the 
lichenoid pattern and damage to the der-
moepidermal junction zone becomes pro-
longed, atrophic scarring occurs, possibly 
by the detrimental action of granzyme B 
expressing skin-homing CLA+CD8+ T 
cells  [22] . A mixed dermal infiltrate of 
dendritic cells (DC) and lymphocytes is 
associated with this process, in a patchy or 
perivascular pattern. Especially the plas-
macytoid DC (pDC), whose principal role 
is to secrete type I interferon, are present 
in cutaneous lupus erythematosus lesions, 
underlining the essential role of type I in-
terferon in lupus erythematosus, which 
has been elegantly and convincingly shown 
 [23–25] . Although the exact role of pDC in 
lupus is unclear, it is known that they are 
activated by DNA complexed with antimi-
crobial peptides  [26] , a process that could 
possibly be enhanced by anti-DNA anti-
bodies  [27, 28] . The accumulation of pDC 
and the expression of the myxovirus pro-
tein A is associated in cutaneous lesions of 
lupus, indicating a local production of 
type I interferons  [29] . Because type I in-
terferon has pleiotropic effects on the im-
mune system, it can greatly enhance the 
accumulation of lymphocytes such as au-
toreactive T cells in the dermoepidermal 
junction of the skin by induction of che-
mokine (C-X-C motif) ligand (CXCL) 9, 
IP-10/CXCL10 and CXCL11, all of which 
recruit CXC-receptor-3-expressing lym-
phocytes such as Th1 CD3+CD4+ and 
CD3+CD8+ T cells. With the major histo-
compatibility complex class II activation 
pattern of CD3+CD4+ T cells that is found 
in both diseases, a pathogenetic relation-
ship has been shown between cutaneous 
and SLE  [30] , and systemic and discoid 
 lupus erythematosus are considered two 
ends of a spectrum.
 Modern Therapeutic Options for 
Cutaneous Lupus Erythematosus 
 First-line agents in the management of 
cutaneous lupus erythematosus are UVR 
protection, high-potency topical cortico-
steroids and antimalarials. Systemic ret-
inoids are second in line, and immu-
nomodulatory/immunosuppressive drugs 
including systemic steroids are considered 
third-line agents  [31–33] . Of all the forms 
of lupus erythematosus, the hypertrophic 
form has proven to be particularly resis-
tant to therapy. To control HLE, an effec-
tive treatment must address both the spe-
cific inflammatory infiltrate as well as the 
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enormous thickening of the epidermis, 
which both seem to be elicited by inflam-
matory T cells. With the advent of new bi-
ologic agents for the treatment of medical 
conditions for which no other satisfactory 
treatment is available, new avenues have 
opened up as well for a pathogenetically 
oriented treatment of orphan diseases. To 
determine the extent of accuracy with 
which a theory describes the pathogenesis, 
an adapted medical treatment addressing 
the suspected disease mediators can yield 
the answers. As early as 1996, in a ground-
breaking case series, 5 cases of severe cu-
taneous lupus erythematosus had been 
successfully treated with the chimeric 
CD4 monoclonal antibody cM-T412  [34] . 
As an early treatment event, the authors 
reported a nearly complete loss of cutane-
ous inflammatory activity after each infu-
sion cycle. Interestingly, autoantibody ti-
ters did not decrease except in 1 patient. 
 More subtle treatment trials for lupus 
erythematosus were later performed with 
the agent efalizumab. This molecule is an 
immunomodulating, specific, recombi-
nant humanized IgG1 antibody for CD11a, 
the   -subunit of lymphocyte function an-
tigen 1 (LFA-1). By blocking the binding of 
LFA-1 to intercellular adhesion molecule 
1, efalizumab inhibits the adhesion of leu-
kocytes to other cell types and interferes 
with the migration of T lymphocytes to the 
sites of inflammation (including psoriatic 
skin plaques). Efalizumab has no direct 
depleting effect, and lymphopenia is not a 
regular side effect. As an additional proof 
of concept without the rather drastic ef-
fects of abolishing the whole CD4+ T cell 
subset  [34] and its beneficial protective re-
sponses, a successful therapy of discoid lu-
pus erythematosus with efalizumab was 
shown in one open study and in case re-
ports  [3, 35, 36] . Along with its efficacious 
action on T cells, this drug can also alter 
DC populations in skin  [37] . 
 Another lymphocyte function antigen 
protein is currently put to medical use in 
the form of an immunomodulatory recep-
tor Fc fusion protein called alefacept. This 
molecule consists of the first extracellular 
domain of LFA-3 fused to the human IgG1 
hinge, CH2 and CH3 domains. It has been 
shown to bind preferentially to lesional T 
cells mainly via the costimulatory and ad-
hesive surface protein CD2, which is usu-
ally expressed on T and NK cells. Because 
of their immunoglobulin fusion part, Fc-
receptor-positive (CD16) cells bind to
targeted lesional T cells and increase ex-
tracellular signal-regulated kinase phos-
phorylation, upregulate the cell surface 
expression of the activation marker CD25 
and induce the release of granzyme B. This 
eventually leads to an apoptosis of CD2+ 
target T cells  [38] , which can lead to rele-
vant but reversible lymphopenia during 
treatment  [39] . However, to our knowl-
edge, no trials have been performed with 
alefacept for lupus erythematosus, except 
for the observation that during the treat-
ment of psoriasis with alefacept, a coexis-
tent subacute cutaneous lupus erythema-
tosus did not exacerbate  [38] . 
 A monoclonal humanized antibody 
against the   4 -subunit of the   1 -integrin is 
called natalizumab. It represents the first 
drug in the class of selective adhesion in-
hibitors and blocks the adhesion of lym-
phocytes to vascular cell adhesion mole-
cule 1 or mucosal vascular addressin cell 
adhesion molecule 1  [40] . In addition, it 
can modulate inflammatory reactions by 
inhibiting the binding of   4 -positive leu-
kocytes with fibronectin and osteopontin. 
It has been shown to decrease the CD4+/
CD8+ ratio in the peripheral blood and ce-
rebrospinal fluid. This antibody might be 
another candidate for treating lupus ery-
thematosus; however, it too is haunted by 
the danger of progressive multifocal leu-
koencephalopathy like its counterpart 
efalizumab.
 Not all types of lupus must be addressed 
by T-cell-directed therapy. Elevated auto-
antibodies against the nucleus, double-
stranded DNA or ribonuclear particles 
(SS-A/B) are an important cornerstone in 
the diagnosis of SLE and subacute cutane-
ous lupus erythematosus. Therefore, the 
pathogenesis of both SLE and subacute cu-
taneous lupus, but probably not of cutane-
ous lupus and HLE, involves a role for 
pathogenic B cells. Because depleting or 
blocking B cells therefore seems to be a 
promising therapeutic strategy, many clin-
ical trials are currently ongoing. In a recent 
review  [41] , in total 17 completed clinical 
trials enrolling 973 patients and 5 ongoing 
studies with an anticipated enrollment of 
785 patients were analyzed. B-cell-deplet-
ing therapies with the monoclonal anti-
bodies rituximab and epratuzu mab result-
ed in good therapeutic effects, unlike treat-
ment with the B cell tolerogen LJP 394, 
which did not demonstrate much clinical 
benefit. Studies targeting costimulatory 
pathways have shown variable results; clin-
ical trials with anti-CD40L antibody were 
terminated because of thromboembolic 
events, whereas studies targeting the B7-
CD28 pathway seem promising. Anticyto-
kine agents against B lymphocyte stimula-
tor, interleukin-10 and -6, and interferon-
  are all interesting agents whose effects
on SLE are not certain yet  [41] . 
 Taken together, our patient’s HLE had 
been controlled by the T-cell-directed efa-
lizumab until the agent was taken from
the market. The options for directed and 
pathogenetically adapted therapy are wid-
ening for lupus and its rarer forms. Bio-
logic therapy is not limited to targeting 
single cell types or cytokines, but can 
break the whole pathogenetic chain, which 
in this case involved lymphocytic infil-
trates and resulting T-cell-dependent epi-
dermal hyperplasia. While the withdrawal 
of efalizumab from the market leaves pa-
tients with psoriasis many other options 
for effective therapy, it disproportionately 
affects patients with T-cell-mediated or-
phan diseases like refractory HLE.
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